Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes

Diabetes and Metabolism

Volumn 38, Issue 4, 2012, Pages 298-308

  Cariou, B ^a  

^a CHU de Nantes   (France)

Author keywords

Cardiovascular disease; Endothelial function; GLP 1; Hypertension; Incretin therapy; Myocardial function; Review; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; LIPID; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MICE; PEPTIDES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 84866755682     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.04.003     Document Type: Review

References (121)

1. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
2. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
3. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
4. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
5. Suh D.C., Choi I.S., Plauschinat C., Kwon J., Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complications 2010, 24:382-391.
6. Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
7. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
8. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
9. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
10. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30:162-172.
11. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
12. Russell M., Silverman A., Fleg J.L., Lee E.T., Mete M., Weir M., et al. Achieving lipid targets in adults with type 2 diabetes: the Stop atherosclerosis in native diabetics study. J Clin Lipidol 2010, 4:435-443.
13. American Diabetes, Association Standards of medical care in diabetes - 2011. Diabetes Care 2011, 34(Suppl. 1):S11-S61.
14. Ban K., Hui S., Drucker D.J., Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009, 3:245-259.
15. Fisman E.Z., Motro M., Tenenbaum A. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol 2008, 45:154-170.
16. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
17. Vergès B., Bonnard C., Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011, 37:477-488.
18. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
19. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture 2005. Diabetologia 2006, 49:253-260.
20. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
21. Meier J.J., Nauck M.A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 2010, 59:1117-1125.
22. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45:1111-1119.
23. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
24. Charbonnel B., Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011, 13:99-117.
25. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
26. Wei Y., Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995, 358:219-224.
27. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagon like peptide-1 7-36 amide and glucagon like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-661.
28. Orskov C., Rabenhøj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
29. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
30. Knudsen L.B., Pridas L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs and acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318:429-435.
31. Vahl T.P., Paty B.W., Fuller B.D., Prigeon R.L., D'Alessio D.A. Effects of GLP-1-(7-36)NH2 GLP-1-(7-37) and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003, 88:1772-1779.
32. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
33. Richter G., Feddersen O., Wagner U., Barth P., Göke R., Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993, 265:L374-L381.
34. Nyström T., Gonon A.T., Sjöholm A., Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177.
35. Ozyazgan S., Kutluata N., Afşar S., Ozdaş S.B., Akkan A.G. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 2005, 74:119-126.
36. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
37. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478:136-142.
38. Barragán J.M., Rodríguez R.E., Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994, 266:E459-E466.
39. Barragán J.M., Eng J., Rodriguez R., Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999, 277:E784-E791.
40. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43-52.
41. Isbil-Buyukcoskun N., Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 2004, 118:33-38.
42. Bojanowska E., Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept 2000, 91:75-81.
43. Grieve D.J., Cassidy R.S., Green B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. Br J Pharmacol 2009, 157:1340-1351.
44. Edwards C.M., Edwards A.V., Bloom S.R. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf. Exp Physiol 1997, 82:709-716.
45. Kavianipour M., Ehlers M.R., Malmberg K., Ronquist G., Ryden L., Wikström G., et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24:569-578.
46. Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003, 21:1125-1135.
47. Bojanowska E., Stempniak B. Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J Endocrinol 2002, 172:303-310.
48. Larsen P.J., Fledelius C., Knudsen L.B., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
49. Moreno C., Mistry M., Roman R.J. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002, 434:163-167.
50. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
51. Bharucha A.E., Charkoudian N., Andrews C.N., Camilleri M., Sletten D., Zinsmeister A.R., et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008, 295:R874-R880.
52. Thrainsdottir I., Malmberg K., Olsson A., Gutniak M., Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004, 1:40-43.
53. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
54. Sokos G.G., Bolukoglu H., German J., Hentosz T., Magovern G.J., Maher T.D., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100:824-829.
55. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
56. Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061.
57. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
58. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
59. Nikolaidis L.A., Doverspike A., Hentosz T., Zourelias L., Shen Y.T., Elahi D., et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005, 312:303-308.
60. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
61. Ravassa S., Zudaire A., Carr R.D., Diez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 2011, 300:H1361-H1372.
62. Sonne D.P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249.
63. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
64. Sauvé M., Ban K., Momen M.A., Zhou Y.Q., Henkelman R.M., Husain M., et al. Genetic deletion of pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073.
65. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl. 1):III27-III32.
66. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
67. Jansson P.A. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007, 262:173-183.
68. Sjoholm A. Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab 2009, 11(Suppl. 3):19-25.
69. Liu H., Hu Y., Simpson R.W., Dear A.E. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol 2008, 196:57-65.
70. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010, 391:1405-2148.
71. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
72. Bertin E., Arner P., Bolinder J., Hagström-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 2001, 86:1229-1234.
73. Perea A., Viñambres C., Clemente F., Villanueva-Peñacarrillo M.L., Valverde I. GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res 1997, 29417-29421.
74. Villanueva-Peñacarrillo M.L., Márquez L., González N., Díaz-Miguel M., Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001, 33:73-77.
75. Sancho V., Trigo M.V., González N., Valverde I., Malaisse W.J., Villanueva-Peñacarrillo M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol 2005, 35:27-38.
76. Sancho V., Trigo M.V., Martín-Duce A., Gonz Lez N., Acitores A., Arnés L., et al. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 2006, 17:1133-1137.
77. Valverde I., Puente J., Martín-Duce A., Molina L., Lozano O., Sancho V., et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005, 15:387-397.
78. Qin X., Shen H., Liu M., Yang Q., Zheng S., Sabo M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949.
79. Hsieh J., Longuet C., Baker C.L., Qin B., Federico L.M., Drucker D.J., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
80. Parlevliet E.T., de Leeuw van Weenen J.E., Romijn J.A., Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2010, 299:E318-E324.
81. Nogueiras R., Pérez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009, 29:5916-5925.
82. Tachibana T., Oikawa D., Adachi N., Boswell T., Furuse M. Intracerebroventricular injection of glucagon-like peptide-1 changes lipid metabolism in chicks. Comp Biochem Physiol A Mol Integr Physiol 2007, 147:1104-1108.
83. Nordestgaard B.G., Benn M., Schnohr P., Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA 2007, 298:299-308.
84. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
85. Duez H., Cariou B., Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 2012, 83:823-832.
86. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
87. Gilbert M.P., Pratley R.E. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Eur J Intern Med 2009, 20(Suppl. 2):S309-S318.
88. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009, 23:463-477.
89. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
90. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
91. Monami M., Iacomelli I., Marchionni N., Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010, 224-235.
92. Griffioen K.J., Wan R., Okun E., Wang X., Lovett-Barr M.R., Li Y., et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011, 89:72-78.
93. Gill A., Hoogwerf B.J., Burger J., Bruce S., Macconell L., Yan P., et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010, 9:6.
94. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
95. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
96. Ratner R.E., Maggs D., Nielsen L.L., Stonehouse A.H., Poon T., Zhang B., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
97. Fonseca V., Madsbad S., Falahati A., Zychma M., Plutzky J. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: a meta-analysis of six clinical trials (LEAD). Diabetes 2009, 58(Suppl. 1). A146. [Abstract].
98. Gallwitz B., Vaag A., Falahati A., Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010, 64:267-276.
99. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
100. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
101. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
102. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
103. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
104. Timmers L., Henriques J.P., de Kleijn D.P., Devries J.H., Kemperman H., Steendijk P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
105. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2011 [Epub ahead of print] doi:10.1093/eurheartj/ehr309.
106. Bao W., Aravindhan K., Alsaid H., Chendrimada T., Szapacs M., Citerone D.R., et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011, 6:e23570.
107. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
108. Liu H., Dear A.E., Knudsen L.B., Simpson R.W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009, 201:59-66.
109. Plutzky J., Poulter N.R., Falahati A., Toft A.D., Davidson M.H. Plasminogen activator inhibitor-1 is reduced by the once-daily human glucagon-like peptide-1 analog liraglutide when used in the treatment of type 2 diabetes. Circulation 2009, 120:S397.
110. Courrèges J.P., Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008, 25:1129-1131.
111. Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courrèges J.P., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
112. Viswanathan P., Chaudhuri A., Bhatia R., Al-Atrash F., Mohanty P., Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007, 13:444-450.
113. Schwartz E.A., Koska J., Mullin M.P., Syoufi I., Schwenke D.C., Reaven P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212:217-222.
114. Bunck M.C., Diamant M., Eliasson B., Corner A., Shaginian R.M., Heine R.J., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010, 33:1734-1737.
115. Marso S.P., Lindsey J.B., Stolker J.M., House J.A., Martinez Ravn G., Kennedy K.F., et al. Cardiovascular safety of liraglutide assessed in a patients-level a pooled analysis from phase 2-3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8:237-240.
116. Monami M. Glucagon-like peptide-1 and diabetes. Exp Diabetes Res 2011, 2011:901954.
117. Goldfine A.B. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008, 359:1092-1095.
118. Bergenstal R., Daniels G., Mann J., et al. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER™): rationale and study design. Diabetes 2011, 60(Suppl .1). 2303. [Abstract].
119. Ratner R., Han J., Nicewarner D., Yushmanova I., Hoogwerf B.J., Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
120. Best J.H., Hoogwerf B.J., Herman W.H., Pelletier E.M., Smith D.B., Wenten M., et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011, 34(1):90-95.
121. Amylin Pharmaceuticals, Inc. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once-weekly in patients with type 2 diabetes mellitus: 2010. Available from: (accessed June 2011). http://clinicaltrials.gov/ct2/show/NCT01144338%3Fterm=exenatide+once-weekly%26rank=9.